- Conditions
- Adverse Drug Interactions
- Interventions
- Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
- Drug · Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 2,297
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alopecia, Chemotherapy-Induced Change, Hair Loss, Alopecia Drugs
- Interventions
- Keratinocyte growth factor
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Head and Neck Cancer
- Interventions
- Gemcitabine, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Risankizumab, Trosunilimab, ABBV-701
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more
- Conditions
- Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- naloxone hydrochloride
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Newly Diagnosed FLT3 Mutated AML
- Interventions
- Crenolanib, Midostaurin, Cytarabine, Duanorubicin
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 31
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- ICT-107, Placebo
- Biological
- Lead sponsor
- Precision Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 43 more
- Conditions
- Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)
- Interventions
- BLINCYTO (Blinatumomab)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Blinatumomab, Lenalidomide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
- Conditions
- Ulcerative Colitis Acute
- Interventions
- Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
- Drug
- Lead sponsor
- Berinstein, Jeffrey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hemodialysis Complication, Hypotension of Hemodialysis
- Interventions
- Lanadelumab Injection [Takhzyro], Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Vorolanib, Atezolizumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neuroblastoma
- Interventions
- Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor, Cyclophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, PBSC, Radiation Therapy, 13-cis-retinoic acid
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Not listed
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
- Interventions
- Vincristine, Sirolimus
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 31 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ginger extract, placebo
- Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 5
- States / cities
- South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Interventions
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT)
- Drug · Procedure · Radiation
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Interventions
- Cryotherapy, Compression Therapy, Loose glove/sock
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chemotherapy-induced Cognitive Impairment
- Interventions
- Neurocognitive assessments
- Behavioral
- Lead sponsor
- Rachel Miller
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
- Interventions
- Revumenib, Midostaurin, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Richard Stone, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Boston, Massachusetts
- Conditions
- Pharmacokinetics
- Interventions
- CC-220, Rifampin, Itraconazole
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Metformin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, pegfilgrastim
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Q-Urol, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Panobinostat
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Columbus, Ohio + 2 more